ALK-Abelló has acquired rights to Neffy adrenaline nasal spray in Europe and Canada, amongst other countries, from ARS ...

Common decongestants may soon be pulled from shelves. The Food and Drug Administration (FDA) announced Wednesday its proposal ...

Researchers have developed a promising nasal spray therapy targeting neuroinflammation in Alzheimer’s disease, potentially ...

A Danish company is spending $145 million upfront for certain rights to the first-ever needle-free adrenaline nasal spray for severe allergic reactions, unlocking sales potential of more than $400 ...

A new therapy may delay Alzheimer's disease progression by years, according to a study by researchers at Texas A&M University ...

Although ARS Pharmaceuticals’ approval for its epinephrine nasal spray came later than expected, the company ultimately received a thumbs up from the FDA in August and is now moving fast to expand ...

ALK and ARS Pharmaceuticals sign a deal giving ALK global rights to Neffy nasal spray outside key regions, targeting peak sales of around $400 million in anaphylaxis treatment.

ARS Pharmaceuticals shares jumped Monday after the company inked a deal to commercialize its allergic reaction nasal spray internationally.

Here’s what you need to know about nasal spray dependency, the symptoms to watch out for, and how to manage withdrawal. When congestion sets in, the cause is typically inflammation in the nasal ...

ALK will initially focus on bringing neffy® to the markets in Europe and Canada, the world's second and third largest adrenaline autoinjector ("AAI”) markets. In both markets, the product can be added ...

Phenylephrine is included in many cold and flu products, but a scientific panel last year found that it doesn't really do its ...

The U.S. Food and Drug Administration is taking the first step to remove an ingredient in non-prescription cold medicines ...